» Articles » PMID: 24360921

Ommaya Reservoir-related Infections: Clinical Manifestations and Treatment Outcomes

Overview
Journal J Infect
Date 2013 Dec 24
PMID 24360921
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: As infection is a severe complication of Ommaya reservoirs (OR), and existing data is limited, herein we describe the largest study of the clinical manifestations and treatment outcomes of Ommaya reservoir-related infections (ORRI).

Methods: We retrospectively reviewed the records of all patients at our institution who had an OR placed, and developed a definite device-related infection between 2001 and 2011.

Results: Among 501 OR placements, 40 patients (8%) developed an ORRI. These presented with meningitis and/or meningoencephalitis (60%), cellulitis (20%), or a combination thereof (20%). Approximately 40% occurred ≤30 days of OR placement, while 60% occurred ≤10 days after the device was last accessed. Only 20% presented with leukocytosis, while another 18% had a normal cerebrospinal fluid (CSF). Gram-positive skin flora accounted >80% of the pathogens. The median hospital stay and duration of antibiotics were 13 and 24 days, respectively. Although mortality rates (≈10%) were similar among all treatment groups (p > 0.99), shorter hospitalization and antimicrobial treatment durations were obtained with early versus late device removal (p < 0.038).

Conclusions: As clinical symptoms can be non-specific and CSF parameters may be within normal limits, a high suspicion for infection is required. The shortest hospitalization and treatment course was achieved with early device removal.

Citing Articles

Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.

Gaietto A, Panetta J, Pauley J, Relling M, Ribeiro R, Ehrhardt M Cancer Chemother Pharmacol. 2024; 93(6):617-625.

PMID: 38416167 PMC: 11376002. DOI: 10.1007/s00280-024-04653-9.


Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model.

Benatti H, Prestigiacomo R, Taghian T, Miller R, King R, Gounis M Mol Ther Methods Clin Dev. 2023; 31:101122.

PMID: 37920238 PMC: 10618110. DOI: 10.1016/j.omtm.2023.101122.


The insertion and management of an external ventricular drain in pediatric patients with hydrocephalus associated with medulloblastoma.

Zhang Z, Wu Y, Zhao X, Zhou J, Li L, Zhai X Neurosurg Rev. 2023; 46(1):170.

PMID: 37433938 DOI: 10.1007/s10143-023-02080-7.


Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

Lazaratos A, Maritan S, Quaiattini A, Darlix A, Ratosa I, Ferraro E Breast. 2023; 69:451-468.

PMID: 37156650 PMC: 10300571. DOI: 10.1016/j.breast.2023.04.008.


Prevention of device-related infections in patients with cancer: Current practice and future horizons.

Viola G, Szvalb A, Malek A, Chaftari A, Hachem R, Raad I CA Cancer J Clin. 2022; 73(2):147-163.

PMID: 36149820 PMC: 9992006. DOI: 10.3322/caac.21756.